🇺🇸 FDA

Company profile · Sponsor

LEO

LEO Pharma A/S

EFF7A71 · EMA pharma Ballerup, DK
Pipeline
6
Drugs
0
Patents
0

Quick answer

LEO (EFF7A71) is a pharma company. headquartered in Ballerup, DK. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EFF7A71
Exchange EMA
Company type pharma
Headquarters Ballerup, DK

Pipeline (6)

Search pipeline →

  1. Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO

    Treatment of moderate-to-severe Atopic dermatitis

    phase 3 small molecule active

    1 trial

  2. Adtralza 150 mg solution for injection in pre-filled syringe

    LEO

    Treatment of moderate-to-severe Atopic dermatitis

    phase 2 small molecule active

    1 trial

  3. Delgocitinib cream, Cream Vehicle

    LEO

    Mild to severe palmoplantar pustulosis

    phase 2 small molecule active

    1 trial

  4. A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases

    LEO

    Gout flares

    phase 1 other active

    1 trial

  5. Brodalumab 70 mg, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP, without the active substance., Kyntheum 210 mg solution for injection in pre-filled syringe

    LEO

    Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.

    approved small molecule active

    1 trial

  6. TRALOKINUMAB, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO

    Atopic dermatitis and moderate-to severe atopic hand eczema

    approved small molecule active

    1 trial

Frequently asked questions

What is LEO?

LEO (EFF7A71) is a pharma company. headquartered in Ballerup, DK. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does LEO sponsor?

We track 6 ClinicalTrials.gov-linked programs for LEO, including Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP. and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does LEO company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.